Recursion Pharmaceuticals (RXRX) News Today $4.14 -0.42 (-9.12%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Rafferty Asset Management LLC Cuts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Rafferty Asset Management LLC decreased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 11.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 595,472 shares of the company's stock after selling 80,319May 21 at 5:28 AM | marketbeat.comRaiffeisen Bank International AG Buys New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Raiffeisen Bank International AG purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 150,000 shares of the company's stock, valued at approxiMay 19 at 6:05 AM | marketbeat.comLazard Asset Management LLC Has $3.76 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Lazard Asset Management LLC lowered its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 555,850 shares of the company's stock after selling 86,458 shares during the period. LMay 19 at 4:43 AM | marketbeat.comSoftbank Group CORP. Invests $99.15 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Softbank Group CORP. acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,667,491 shares of the company's stock, vMay 18 at 7:17 AM | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Northern Trust CorpNorthern Trust Corp boosted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 18.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 2,394,511 shares of the company's stock after acquiring an additional 371,886 shares duMay 17, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Nosedives 36.55% As AI Drug Discovery Dreams StallMay 15, 2025 | insidermonkey.comRecursion Pharmaceuticals: High-Risk Play Getting Riskier By The QuarterMay 14, 2025 | seekingalpha.comRecursion Pharmaceuticals, Inc. (RXRX): Among the Best Artificial Intelligence Stocks Under $50 to Buy NowMay 14, 2025 | msn.comLaurion Capital Management LP Invests $16.61 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Laurion Capital Management LP bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,457,189May 14, 2025 | marketbeat.comShould You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?May 12, 2025 | fool.com2 Top Artificial Intelligence (AI) Stocks to Buy Right NowMay 11, 2025 | fool.comLeerink Partnrs Has Bullish Estimate for RXRX Q2 EarningsRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Equities researchers at Leerink Partnrs lifted their Q2 2025 EPS estimates for Recursion Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now expects that theMay 10, 2025 | marketbeat.comRaymond James Financial Inc. Acquires New Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Raymond James Financial Inc. purchased a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 90,107 shares of the company's stock, valued atMay 10, 2025 | marketbeat.comWhy Recursion Pharmaceuticals Stock Plummeted 24% This WeekMay 9, 2025 | fool.com66,900 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Bought by Bayesian Capital Management LPBayesian Capital Management LP bought a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 66,900 shares of the company's stock, valuMay 9, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.4% Following Weak EarningsRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.4% on Disappointing EarningsMay 8, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Receives a Hold from TD CowenMay 7, 2025 | theglobeandmail.comNeedham & Company LLC Cuts Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $8.00Needham & Company LLC lowered their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday.May 7, 2025 | marketbeat.comEarnings Release: Here's Why Analysts Cut Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target To US$7.43May 7, 2025 | finance.yahoo.comCasdin Capital LLC Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Casdin Capital LLC purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 165,323 shares of the company's stock, valued atMay 7, 2025 | marketbeat.comWhy Recursion Pharmaceuticals Stock Is Plummeting TodayMay 6, 2025 | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 9.6% on Disappointing EarningsRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 9.6% on Disappointing EarningsMay 6, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down on Disappointing EarningsRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down After Earnings MissMay 6, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPSRecursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%.May 6, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPSRecursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%.May 6, 2025 | marketbeat.comRecursion to Participate in Upcoming Investor ConferencesMay 6, 2025 | globenewswire.comRecursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial ResultsMay 5, 2025 | finance.yahoo.comWhy Recursion Pharmaceuticals Stock Was Getting Mashed on MondayMay 5, 2025 | fool.comRecursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comRetail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial DataMay 5, 2025 | msn.comRecursion Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 5, 2025 | globenewswire.comRecursion Pharmaceuticals: Looking For Entry Around Q1 EarningsMay 5, 2025 | seekingalpha.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 5% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 5% Higher - What's Next?May 5, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Takes Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Susquehanna Fundamental Investments LLC acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 130,443 shares oMay 5, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of "Hold" from BrokeragesRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has been assigned an average recommendation of "Hold" from the six analysts that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and two have assigned a buy rating toMay 5, 2025 | marketbeat.comPreliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp BurdenMay 4, 2025 | globenewswire.comInvesco Ltd. Purchases 63,068 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Invesco Ltd. lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 54.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 178,619 shares of the company's stoMay 4, 2025 | marketbeat.comNovo Holdings A S Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Novo Holdings A S acquired a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,114,633 shares of the company's stocMay 3, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by RA Capital Management L.P.RA Capital Management L.P. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 49.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 7,725,096 shares of the company's stock after selling 7,659,519 shares during the pMay 3, 2025 | marketbeat.comRecursion Pharmaceuticals Q1 2025 Earnings PreviewMay 2, 2025 | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.6% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.6% - Time to Sell?May 1, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Expected to Announce Earnings on MondayRecursion Pharmaceuticals (NASDAQ:RXRX) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-recursion-pharmaceuticals-inc-stock/)May 1, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.8% Higher - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.8% Higher - Time to Buy?April 30, 2025 | marketbeat.comWas Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?April 29, 2025 | finance.yahoo.comBarclays PLC Has $4.28 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Barclays PLC reduced its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 9.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 633,125 shares of the company's stock after selling 64,307 shareApril 29, 2025 | marketbeat.comRecursion to Report First Quarter 2025 Business Updates and Financial Results on May 5thApril 28, 2025 | globenewswire.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 1.3% Higher - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1.3% - Still a Buy?April 26, 2025 | marketbeat.comLegal & General Group Plc Raises Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Legal & General Group Plc raised its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 26.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 253,426 shares of the company's stApril 26, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1.9% - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 1.9% - What's Next?April 25, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 5.5% - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.5% Higher - What's Next?April 24, 2025 | marketbeat.com Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Videos RXRX Media Mentions By Week RXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXRX News Sentiment▼1.240.65▲Average Medical News Sentiment RXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXRX Articles This Week▼89▲RXRX Articles Average Week Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Elanco Animal Health News Today Blueprint Medicines News Today BridgeBio Pharma News Today Verona Pharma News Today Telix Pharmaceuticals Limited American Depositary Shares News Today Grifols News Today TG Therapeutics News Today Lantheus News Today Axsome Therapeutics News Today Legend Biotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXRX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RXRX Stock Free RXRX Stock Alerts